Inhibition of arachidonic acid metabolism and its implication on cell proliferation and tumour-angiogenesis.
暂无分享,去创建一个
[1] U. Kelavkar,et al. Overexpression of 15-lipoxygenase-1 in PC-3 human prostate cancer cells increases tumorigenesis. , 2001, Carcinogenesis.
[2] Marta L. Capone,et al. New insights into COX-2 biology and inhibition , 2005, Brain Research Reviews.
[3] F. Cianchi,et al. Inhibition of 5-lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cells , 2006, Molecular Cancer Therapeutics.
[4] S. Biswal,et al. The 5-lipoxygenase-activating protein (FLAP) inhibitor, MK886, induces apoptosis independently of FLAP. , 1999, The Biochemical journal.
[5] Shuji Ogino,et al. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. , 2007, The New England journal of medicine.
[6] L. Magnelli,et al. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. , 2001, Neoplasia.
[7] S. Grösch,et al. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. , 2006, Journal of the National Cancer Institute.
[8] H. Ateş,et al. Cyclo-oxygenase 2 inhibitor, nabumetone, inhibits proliferation in chronic myeloid leukemia cell lines , 2005, Leukemia & lymphoma.
[9] Charles N. Serhan,et al. Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their endogenous aspirin-triggered epimers , 2004, Lipids.
[10] A. K. Katz,et al. The 2.0 A resolution crystal structure of prostaglandin H2 synthase-1: structural insights into an unusual peroxidase. , 2004, Journal of molecular biology.
[11] A. Tenesa,et al. Dietary fatty acids and colorectal cancer: a case-control study. , 2007, American journal of epidemiology.
[12] J. Redfern,et al. Role of endogenous prostaglandins in preventing gastrointestinal ulceration: induction of ulcers by antibodies to prostaglandins. , 1989, Gastroenterology.
[13] S. Lippman,et al. Advances in the biology of lung cancer chemoprevention. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] P. Loll,et al. Structural analysis of NSAID binding by prostaglandin H2 synthase: time-dependent and time-independent inhibitors elicit identical enzyme conformations. , 2001, Biochemistry.
[15] M. Fornai,et al. Efficacy and Tolerability of Meloxicam, a COX-2 Preferential Nonsteroidal Anti-Inflammatory Drug , 2002 .
[16] C. Serhan,et al. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[17] L. Audoly,et al. The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis. , 2002, The Journal of clinical investigation.
[18] R. DuBois,et al. 15-LOX-1 inhibits p21 (Cip/WAF 1) expression by enhancing MEK-ERK1/2 signaling in colon carcinoma cells , 2004 .
[19] R. Gaynor,et al. Sulindac inhibits activation of the NF-kappaB pathway. , 1999, The Journal of biological chemistry.
[20] J. Kleibeuker,et al. Non-steroidal anti-inflammatory drugs and molecular carcinogenesis of colorectal carcinomas , 2003, The Lancet.
[21] A. Brash,et al. A single active site residue directs oxygenation stereospecificity in lipoxygenases: stereocontrol is linked to the position of oxygenation. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[22] M. Clynes,et al. Structure-activity relationship of indomethacin analogues for MRP-1, COX-1 and COX-2 inhibition. identification of novel chemotherapeutic drug resistance modulators. , 2002, European journal of cancer.
[23] Y. Kawahito,et al. Relationship between lipoxygenase and human testicular cancer. , 2004, International journal of molecular medicine.
[24] T. Ichikura,et al. Expression of cyclooxygenase‐2 in human gastric adenomas and adenocarcinomas , 2001, Journal of surgical oncology.
[25] B. Psaty,et al. COX-2 inhibitors--lessons in drug safety. , 2005, The New England journal of medicine.
[26] R. DuBois,et al. Cyclooxygenase 2-derived prostaglandin E2 regulates the angiogenic switch. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[27] S. Daya,et al. Non-steroidal anti-inflammatory agents, tolmetin and sulindac, attenuate oxidative stress in rat brain homogenate and reduce quinolinic acid-induced neurodegeneration in rat hippocampal neurons , 2006, Metabolic Brain Disease.
[28] D. Grignon,et al. Increased metastatic potential in human prostate carcinoma cells by overexpression of arachidonate 12-lipoxygenase , 2004, Clinical & Experimental Metastasis.
[29] M. De Brabander,et al. Measurement of in vivo rectal mucosal cytokine and eicosanoid production in ulcerative colitis using filter paper , 2000, Gut.
[30] C. Pan,et al. Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia. , 2001, Anticancer research.
[31] A. Brash. Lipoxygenases: Occurrence, Functions, Catalysis, and Acquisition of Substrate* , 1999, The Journal of Biological Chemistry.
[32] N. Narayanan,et al. Docosahexaenoic acid regulated genes and transcription factors inducing apoptosis in human colon cancer cells. , 2001, International journal of oncology.
[33] T. Grosser,et al. Role of Prostacyclin in the Cardiovascular Response to Thromboxane A2 , 2002, Science.
[34] Vincent Bours,et al. Reactive Oxygen Intermediate-Dependent NF-κB Activation by Interleukin-1β Requires 5-Lipoxygenase or NADPH Oxidase Activity , 1999, Molecular and Cellular Biology.
[35] G. Landberg,et al. Expression of the leukotriene D4 receptor CysLT1, COX-2, and other cell survival factors in colorectal adenocarcinomas. , 2003, Gastroenterology.
[36] M. Stampfer,et al. A Prospective Study of Polyunsaturated Fatty Acid Levels in Blood and Prostate Cancer Risk , 2007, Cancer Epidemiology Biomarkers & Prevention.
[37] R. Dixon,et al. Correlation between expression of 5-lipoxygenase-activating protein, 5-lipoxygenase, and cellular leukotriene synthesis. , 1990, The Journal of biological chemistry.
[38] J. Wallace,et al. The therapeutic potential of NO‐NSAIDs , 2003, Fundamental & clinical pharmacology.
[39] R. Sandler,et al. Chemoprevention of gastrointestinal malignancies with nonsteroidal antiinflammatory drugs , 2002, Cancer.
[40] Takao Shimizu,et al. A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. , 2000, The Journal of experimental medicine.
[41] A. Solhaug,et al. Atypical lambda/iota PKC conveys 5-lipoxygenase/leukotriene B4-mediated cross-talk between phospholipase A2s regulating NF-kappa B activation in response to tumor necrosis factor-alpha and interleukin-1beta. , 2001, The Journal of biological chemistry.
[42] R. Gaynor,et al. Sulindac Inhibits Activation of the NF-κB Pathway* , 1999, The Journal of Biological Chemistry.
[43] C. Moon,et al. Phenidone, a dual inhibitor of cyclooxygenases and lipoxygenases, ameliorates rat paralysis in experimental autoimmune encephalomyelitis by suppressing its target enzymes , 2005, Brain Research.
[44] Wei Li,et al. Effects of a cyclooxygenase-1-selective inhibitor in a mouse model of ovarian cancer, administered alone or in combination with ibuprofen, a nonselective cyclooxygenase inhibitor , 2009, Medical oncology.
[45] J. Palmblad,et al. Interactions Between Lipoxin A4, the Stable Analogue 16‐phenoxy‐lipoxin A4 and Leukotriene B4 in Cytokine Generation by Human Monocytes , 2004, Scandinavian journal of immunology.
[46] I. Zachary,et al. Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen‐activated protein kinase , 1997, FEBS letters.
[47] B. Wong,et al. 15-Lipoxygenase-1 mediates cyclooxygenase-2 inhibitor-induced apoptosis in gastric cancer. , 2003, Carcinogenesis.
[48] J. Falgueyret,et al. Identification of 5-keto-(7E,9E,11Z,14Z)-eicosatetraenoic acid as a novel nonenzymatic rearrangement product of leukotriene A4. , 1993, Archives of biochemistry and biophysics.
[49] J. Reginster,et al. First clinical results of licofelone (ml3000), an inhibitor of COX-1, COX-2 and 5-LOX, for the treatment of osteoarthritis , 2002 .
[50] R. Kurumbail,et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents , 1997, Nature.
[51] G. Davı̀,et al. 5‐Lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[52] A. Brash,et al. Discovery of a second 15S-lipoxygenase in humans. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[53] Gong Shusheng,et al. Inhibitory effects of Celecoxib and Sc-58125 on proliferation of human carcinoma of larynx Hep-2in vitro , 2008, Journal of Huazhong University of Science and Technology [Medical Sciences].
[54] Sam W. Lee,et al. Suppression of tumor cell growth both in nude mice and in culture by n-3 polyunsaturated fatty acids: mediation through cyclooxygenase-independent pathways. , 2019, Cancer research.
[55] M. Jett,et al. Control of the growth of human breast cancer cells in culture by manipulation of arachidonate metabolism , 2007, BMC Cancer.
[56] M. Thun,et al. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. , 2007, Journal of the National Cancer Institute.
[57] J. Falck,et al. Inhibitors of cytochrome P450 4A suppress angiogenic responses. , 2005, The American journal of pathology.
[58] Jingxia Li,et al. Nickel Compounds Render Anti-apoptotic Effect to Human Bronchial Epithelial Beas-2B Cells by Induction of Cyclooxygenase-2 through an IKKβ/p65-dependent and IKKα- and p50-independent Pathway* , 2006, Journal of Biological Chemistry.
[59] K. Kinzler,et al. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[60] J. Faivre,et al. Chemoprevention of colorectal cancer. , 1999, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[61] Y. Urade,et al. Prostaglandin D, E, and F synthases. , 1995, Journal of lipid mediators and cell signalling.
[62] T. Tsukamoto,et al. Carcinogenesis in mouse stomach by simultaneous activation of the Wnt signaling and prostaglandin E2 pathway. , 2006, Gastroenterology.
[63] R. Estabrook,et al. Liver microsomal cytochrome P-450 and the oxidative metabolism of arachidonic acid. , 1981, Proceedings of the National Academy of Sciences of the United States of America.
[64] H. Vapaatalo,et al. Effects of phenacetin and its metabolite p-phenetidine on COX-1 and COX-2 activities and expression in vitro. , 2003, Thrombosis research.
[65] P. Zou,et al. Role of Baicalein in the regulation of proliferation and apoptosis in human myeloma RPMI8226 cells. , 2006, Chinese medical journal.
[66] Shadan Ali,et al. A novel copper complex of 3‐benzoyl‐α methyl benzene acetic acid with antitumor activity mediated via cyclooxygenase pathway , 2007 .
[67] Michael J Thun,et al. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. , 2002, Journal of the National Cancer Institute.
[68] F. Gürdöl,et al. The effect of COX-2 inhibitor, nimesulide, on angiogenetic factors in primary endometrial carcinoma cell culture , 2007, Clinical and Experimental Medicine.
[69] T. Poulos. Cytochrome P450: Molecular Architecture, Mechanism, and Prospects for Rational Inhibitor Design , 1988, Pharmaceutical Research.
[70] L. Audoly,et al. The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis. , 2002, The Journal of clinical investigation.
[71] J. Falgueyret,et al. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX‐2 inhibitor , 1997, British journal of pharmacology.
[72] T. Hla,et al. Overexpression of Cyclooxygenase-2 Is Sufficient to Induce Tumorigenesis in Transgenic Mice* , 2001, The Journal of Biological Chemistry.
[73] R. Hanf,et al. Cyclo‐oxygenase and lipoxygenase pathways in mast cell dependent‐neurogenic inflammation induced by electrical stimulation of the rat saphenous nerve , 2001, British Journal of Pharmacology.
[74] Y. Kawahito,et al. Expression of lipoxygenase in human bladder carcinoma and growth inhibition by its inhibitors. , 2003, The Journal of urology.
[75] J. Morrow,et al. A selective cyclooxygenase 2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells. , 1997, Gastroenterology.
[76] D. Zeldin,et al. Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. , 2005, Cancer research.
[77] Jilly F. Evans,et al. Characterization of the Human Cysteinyl Leukotriene 2 Receptor* , 2000, The Journal of Biological Chemistry.
[78] C. Godson,et al. Lipoxins: potential anti-inflammatory, proresolution, and antifibrotic mediators in renal disease. , 2004, Kidney international.
[79] D. Richel,et al. Prostanoids and prostanoid receptors in signal transduction. , 2004, The international journal of biochemistry & cell biology.
[80] N. V. Chandrasekharan,et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[81] R. Busse,et al. Cytochrome P450 epoxygenases 2C8 and 2C9 are implicated in hypoxia-induced endothelial cell migration and angiogenesis , 2005, Journal of Cell Science.
[82] D. Gilroy,et al. Targeting lipoxygenases with care. , 2006, Chemistry & biology.
[83] R. Mansel,et al. Levels of expression of lipoxygenases and cyclooxygenase-2 in human breast cancer. , 2003, Prostaglandins, leukotrienes, and essential fatty acids.
[84] C. Lines,et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. , 2005, The New England journal of medicine.
[85] T. Moody,et al. Five‐lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[86] C. Lush,et al. Regulation of intestinal nuclear factor-kappaB activity and E-selectin expression during sepsis: a role for peroxynitrite. , 2003, Gastroenterology.
[87] S. Shahzidi,et al. The effect of cyclooxygenase inhibitor diclofenac on experimental murine colon carcinoma. , 2003, Anticancer research.
[88] M. Burdick,et al. Cyclooxygenase-2-Dependent Expression of Angiogenic CXC Chemokines ENA-78/CXC Ligand (CXCL) 5 and Interleukin-8/CXCL8 in Human Non-Small Cell Lung Cancer , 2004, Cancer Research.
[89] Lois E. H. Smith,et al. Increased dietary intake of ω-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis , 2007, Nature Medicine.
[90] T. Inoue,et al. Effects of nimesulide, a cyclooxygenase-2 selective inhibitor, on colitis induced tumors , 2008, Inflammopharmacology.
[91] R. Makuch,et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. , 2000, JAMA.
[92] K. Hasegawa,et al. Expression of cyclooxygenase-2 in uterine endometrial cancer and anti-tumor effects of a selective COX-2 inhibitor. , 2005, International journal of oncology.
[93] K. Hamada,et al. Etodolac, a selective cyclooxygenase-2 inhibitor, induces upregulation of E-cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo. , 2008, Urology.
[94] B. Anderson. Paracetamol (Acetaminophen): mechanisms of action , 2008, Paediatric anaesthesia.
[95] C. Serhan. A search for endogenous mechanisms of anti-inflammation uncovers novel chemical mediators: missing links to resolution , 2004, Histochemistry and Cell Biology.
[96] C. Hawkey,et al. COX‐LOX INHIBITION: CURRENT EVIDENCE FOR AN EMERGING NEW THERAPY , 2003, International journal of clinical practice.
[97] R. de Caterina,et al. The omega-3 fatty acid docosahexaenoate attenuates endothelial cyclooxygenase-2 induction through both NADP(H) oxidase and PKCε inhibition , 2006, Proceedings of the National Academy of Sciences.
[98] I. Weinstein,et al. Role of COX-independent targets of NSAIDs and related compounds in cancer prevention and treatment. , 2003, Progress in experimental tumor research.
[99] R Day,et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.
[100] R. Busse,et al. Cytochrome P450 2C9-induced Endothelial Cell Proliferation Involves Induction of Mitogen-activated Protein (MAP) Kinase Phosphatase-1, Inhibition of the c-Jun N-terminal Kinase, and Up-regulation of Cyclin D1* , 2002, The Journal of Biological Chemistry.
[101] K. Malik,et al. 20-Hydroxyeicosatetraenoic acid mediates calcium/calmodulin-dependent protein kinase II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[102] W. Zhou,et al. Effects of Nonselective Cyclooxygenase Inhibition with Low-Dose Ibuprofen on Tumor Growth, Angiogenesis, Metastasis, and Survival in a Mouse Model of Colorectal Cancer , 2005, Clinical Cancer Research.
[103] Y. Hannun,et al. Phospholipase A2 Is Necessary for Tumor Necrosis Factor α-induced Ceramide Generation in L929 Cells* , 1997, The Journal of Biological Chemistry.
[104] E. Sigal,et al. Defining the Arachidonic Acid Binding Site of Human 15-Lipoxygenase , 1996, The Journal of Biological Chemistry.
[105] D. Goldenberg,et al. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. , 2002, Cancer research.
[106] A. Plückthun,et al. Rate-determining Step in Phospholipase A2 Mechanism , 1986 .
[107] T. Uzu,et al. Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. , 2007, Internal medicine.
[108] Hee-Yong Kim. Novel Metabolism of Docosahexaenoic Acid in Neural Cells* , 2007, Journal of Biological Chemistry.
[109] I. Okayasu,et al. Cyclooxygenase-2 and inducible nitric oxide synthase expression in human astrocytic gliomas: correlation with angiogenesis and prognostic significance , 2004, Acta Neuropathologica.
[110] S. Narumiya,et al. Prostaglandin E2 is required for ultraviolet B-induced skin inflammation via EP2 and EP4 receptors , 2007, Laboratory Investigation.
[111] Guo-xian Ding,et al. Expression of cyclooxygenase-2 and matrix metalloproteinase-9 in gastric carcinoma and its correlation with angiogenesis. , 2005, Japanese journal of clinical oncology.
[112] L. Battistini,et al. N-3 PUFAs reduce oxidative stress in ESRD patients on maintenance HD by inhibiting 5-lipoxygenase activity. , 2006, Kidney international.
[113] R. Kamijo,et al. Inhibitors of cyclooxygenase-2 (COX-2) suppressed the proliferation and differentiation of human leukaemia cell lines. , 2001, European journal of cancer.
[114] R. DuBois,et al. The role of cyclooxygenases in inflammation, cancer, and development , 1999, Oncogene.
[115] S. Lippman,et al. Lipoxygenase modulation to reverse carcinogenesis. , 2001, Cancer research.
[116] J. Dogné,et al. New trends in dual 5-LOX/COX inhibition. , 2002, Current medicinal chemistry.
[117] S. Narumiya,et al. Prostaglandin D2 as a mediator of allergic asthma. , 2000, Science.
[118] Luhua Lai,et al. Dynamic Simulations on the Arachidonic Acid Metabolic Network , 2007, PLoS Comput. Biol..
[119] S. Dey,et al. Host cyclooxygenase-2 modulates carcinoma growth. , 2000, The Journal of clinical investigation.
[120] H. Friess,et al. 5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. , 2002, The American journal of pathology.
[121] R. de Caterina,et al. The omega-3 fatty acid docosahexaenoate attenuates endothelial cyclooxygenase-2 induction through both NADP(H) oxidase and PKC epsilon inhibition. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[122] A. Murakami,et al. New class of linoleic acid metabolites biosynthesized by corn and rice lipoxygenases: suppression of proinflammatory mediator expression via attenuation of MAPK- and Akt-, but not PPARgamma-, dependent pathways in stimulated macrophages. , 2005, Biochemical pharmacology.
[123] J. Haeggström. Leukotriene A4 Hydrolase/Aminopeptidase, the Gatekeeper of Chemotactic Leukotriene B4 Biosynthesis* , 2004, Journal of Biological Chemistry.
[124] D. Reed,et al. Nonsteroidal antiinflammatory drugs cause apoptosis and induce cyclooxygenases in chicken embryo fibroblasts. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[125] S. Higuchi,et al. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. , 1994, Prostaglandins.
[126] P. Calder,et al. Conversion of alpha-linolenic acid to longer-chain polyunsaturated fatty acids in human adults. , 2005, Reproduction, nutrition, development.
[127] R. Sartor,et al. Low Endogenous Prostaglandin E2 Predisposes to Relapsing Inflammation in Experimental Rat Enterocolitis , 2004, Digestive Diseases and Sciences.
[128] Marc A Pfeffer,et al. Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention , 2005, The New England journal of medicine.
[129] P. Jakobsson,et al. Inhibition of prostaglandin E2 synthesis by SC‐560 is independent of cyclooxygenase 1 inhibition , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[130] Y. Kakeji,et al. Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer. , 1997, Anticancer research.
[131] A. Solhaug,et al. Atypical λ/ιPKC Conveys 5-Lipoxygenase/Leukotriene B4-mediated Cross-talk between Phospholipase A2s Regulating NF-κB Activation in Response to Tumor Necrosis Factor-α and Interleukin-1β* , 2001, The Journal of Biological Chemistry.
[132] P. Ridker,et al. Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[133] M. Jaye,et al. Activation of Cytosolic Phospholipase A by Basic Fibroblast Growth Factor via a p42 Mitogen-activated Protein Kinase-dependent Phosphorylation Pathway in Endothelial Cells (*) , 1995, The Journal of Biological Chemistry.
[134] M. Hetzel,et al. Inhibition of MMP-9 expression by PPARγ activators in human bronchial epithelial cells , 2003, Thorax.
[135] S. Solomon,et al. Celecoxib for the prevention of colorectal adenomatous polyps. , 2006, The New England journal of medicine.
[136] R. Kurumbail,et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents , 1996, Nature.
[137] Sebastian Schneeweiss,et al. Relationship Between Selective Cyclooxygenase-2 Inhibitors and Acute Myocardial Infarction in Older Adults , 2004, Circulation.
[138] S. Kulkarni,et al. Cyclooxygenase isoenzymes and newer therapeutic potential for selective COX-2 inhibitors. , 2000, Methods and findings in experimental and clinical pharmacology.
[139] T. Miller,et al. Protection against ethanol injury by prostaglandin in a human intestinal cell line: role of microtubules. , 1998, American journal of physiology. Gastrointestinal and liver physiology.
[140] J. Dyerberg,et al. The composition of food consumed by Greenland Eskimos. , 2009, Acta medica Scandinavica.
[141] J. Emberson,et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials , 2006, BMJ : British Medical Journal.
[142] T. Schnitzer,et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial , 2004, The Lancet.
[143] N. Bundred,et al. Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence , 2006, British Journal of Cancer.
[144] N. Ishiguro,et al. Meloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent and independent routes. , 2006, Carcinogenesis.
[145] M. Kralj,et al. Fenoprofen and Ketoprofen Amides as Potential Antitumor Agents , 2007, Chemical biology & drug design.
[146] K. Lundholm,et al. EP1–4 subtype, COX and PPARγ receptor expression in colorectal cancer in prediction of disease‐specific mortality , 2007, International journal of cancer.
[147] I. Morita. Distinct functions of COX-1 and COX-2. , 2002, Prostaglandins & other lipid mediators.
[148] R. McLeod,et al. Nonsteroidal Anti-inflammatory Drugs and Aspirin for the Prevention of Colorectal Adenomas and Cancer: A Systematic Review , 2004, Diseases of the colon and rectum.
[149] E. Fernandes,et al. The metabolism of sulindac enhances its scavenging activity against reactive oxygen and nitrogen species. , 2003, Free radical biology & medicine.
[150] D. Frisbie,et al. Nonsteroidal antiinflammatory drugs. , 1981, Delaware medical journal.
[151] Dairong Wang,et al. Cardiovascular hazard and non-steroidal anti-inflammatory drugs. , 2005, Current opinion in pharmacology.
[152] J. Rokach,et al. Biochemistry, biology and chemistry of the 5-lipoxygenase product 5-oxo-ETE. , 2005, Progress in lipid research.
[153] B. Thiele,et al. The diversity of the lipoxygenase family , 1999, FEBS letters.
[154] J. Pelletier,et al. The shunt from the cyclooxygenase to lipoxygenase pathway in human osteoarthritic subchondral osteoblasts is linked with a variable expression of the 5-lipoxygenase-activating protein , 2006, Arthritis research & therapy.
[155] T. Eling,et al. Opposing Effects of 15-Lipoxygenase-1 and -2 Metabolites on MAPK Signaling in Prostate , 2002, The Journal of Biological Chemistry.
[156] F. Traganos,et al. Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIDs) alter the kinetics of human colon cancer cell lines more effectively than traditional NSAIDs: implications for colon cancer chemoprevention. , 2001, Cancer research.
[157] P. van’t Veer,et al. Adipose tissue omega-3 and omega-6 fatty acid content and breast cancer in the EURAMIC study. European Community Multicenter Study on Antioxidants, Myocardial Infarction, and Breast Cancer. , 1998, American journal of epidemiology.
[158] Lawrence J Marnett,et al. A Novel Mechanism of Cyclooxygenase-2 Inhibition Involving Interactions with Ser-530 and Tyr-385* , 2003, Journal of Biological Chemistry.
[159] J. Fraumeni,et al. Cancer mortality among Alaskan natives, 1960-69. , 1975, Journal of the National Cancer Institute.
[160] J. Falck,et al. Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase. , 2000, Journal of lipid research.
[161] P. Loll,et al. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1 , 1994, Nature.
[162] J. J. Moreno,et al. Role of EP(1) and EP(4) PGE(2) subtype receptors in serum-induced 3T6 fibroblast cycle progression and proliferation. , 2002, American journal of physiology. Cell physiology.
[163] N. Abraham,et al. Overexpression of the Heme Oxygenase Gene in Renal Cell Carcinoma , 1997, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[164] M. Murakami,et al. Different functional aspects of the group II subfamily (Types IIA and V) and type X secretory phospholipase A(2)s in regulating arachidonic acid release and prostaglandin generation. Implications of cyclooxygenase-2 induction and phospholipid scramblase-mediated cellular membrane perturbation. , 1999, The Journal of biological chemistry.
[165] A. Brash,et al. 15-lipoxygenase-2 (15-LOX-2) is expressed in benign prostatic epithelium and reduced in prostate adenocarcinoma. , 1999, The American journal of pathology.
[166] D. Elder,et al. The cyclooxygenase 2-selective inhibitor NS398 inhibits proliferation of oral carcinoma cell lines by mechanisms dependent and independent of reduced prostaglandin E2 synthesis. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[167] S. Matsumoto,et al. Novel Antiarthritic Agents with 1,2‐Isothiazolidine‐1,1‐dioxide (γ‐Sultam) Skeleton: Cytokine Suppressive Dual Inhibitors of Cyclooxygenase‐2 and 5‐Lipoxygenase. , 2000 .
[168] J. Falgueyret,et al. Sensitivity of immunoaffinity-purified porcine 5-lipoxygenase to inhibitors and activating lipid hydroperoxides. , 1989, Biochemical pharmacology.
[169] M. Laviolette,et al. Inhibitory effects of MK‐886 on arachidonic acid metabolism in human phagocytes , 1990, British journal of pharmacology.
[170] L. Marnett,et al. Covalent modification of cyclooxygenase-2 (COX-2) by 2-acetoxyphenyl alkyl sulfides, a new class of selective COX-2 inactivators. , 1998, Journal of medicinal chemistry.
[171] I. Weinstein,et al. Select Cyclic Nucleotide Phosphodiesterase Inhibitors in Colon Tumor Chemoprevention and Chemotherapy , 2004 .
[172] C. Serhan,et al. Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-κB and AP-1 activation, and IL-8 gene expression in human leukocytes , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[173] C. Sen,et al. Antioxidant and redox regulation of gene transcription , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[174] K. Druey,et al. Prostaglandin E2 Promotes Colon Cancer Cell Growth Through a Gs-Axin-ß-Catenin Signaling Axis , 2005, Science.
[175] N. Farman,et al. Segmental synthesis and actions of prostaglandins along the nephron. , 1987, The American journal of physiology.
[176] J. Falgueyret,et al. LTA4-derived 5-oxo-eicosatetraenoic acid: pH-dependent formation and interaction with the LTB4 receptor of human polymorphonuclear leukocytes , 2000 .
[177] V. Ziboh,et al. Biological significance of essential fatty acids/prostanoids/ lipoxygenase-derived monohydroxy fatty acids in the skin , 2002, Archives of pharmacal research.
[178] D. Beer,et al. Overexpression of 5-Lipoxygenase in Rat and Human Esophageal Adenocarcinoma and Inhibitory Effects of Zileuton and Celecoxib on Carcinogenesis , 2004, Clinical Cancer Research.
[179] R. Hunt,et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events , 2003, American Journal of Gastroenterology.
[180] G. Watkins,et al. Reduction of isoforms of 15-lipoxygenase (15-LOX)-1 and 15-LOX-2 in human breast cancer. , 2006, Prostaglandins, leukotrienes, and essential fatty acids.
[181] J. Schwab,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[182] S. Ishii,et al. Mutagenesis studies on the amino acid residues involved in the iron-binding and the activity of human 5-lipoxygenase. , 1992, Biochemical and biophysical research communications.
[183] M. Leshno,et al. MF tricyclic and sulindac retard tumor formation in an animal model , 2006, International journal of cancer.
[184] L. Horrocks,et al. Signaling and interplay mediated by phospholipases A2, C, and D in LA-N-1 cell nuclei. , 2005, Reproduction, nutrition, development.
[185] J. J. Moreno,et al. Hydroxyeicosatetraenoic acids released through the cytochrome P-450 pathway regulate 3T6 fibroblast growth Published, JLR Papers in Press, September 16, 2006. , 2006, Journal of Lipid Research.
[186] C. Serhan,et al. Resolvins , 2002, The Journal of experimental medicine.
[187] Hiromasa Hashimoto,et al. 4-(4-cycloalkyl/aryl-oxazol-5-yl)benzenesulfonamides as selective cyclooxygenase-2 inhibitors: enhancement of the selectivity by introduction of a fluorine atom and identification of a potent, highly selective, and orally active COX-2 inhibitor JTE-522(1). , 2002, Journal of medicinal chemistry.
[188] D. Riendeau,et al. Cyclo-oxygenase-2 contributes to constitutive prostanoid production in rat kidney and brain. , 2005, The Biochemical journal.
[189] S. Laufer,et al. The mechanism of action of the new antiinflammatory compound ML3000: inhibition of 5-LOX and COX-1/2 , 2002, Inflammation Research.
[190] Charles N. Serhan,et al. Resolvin E1 Selectively Interacts with Leukotriene B4 Receptor BLT1 and ChemR23 to Regulate Inflammation1 , 2007, The Journal of Immunology.
[191] Jian-Kang Chen,et al. Cytochrome P450 Epoxygenase Metabolism of Arachidonic Acid Inhibits Apoptosis , 2001, Molecular and Cellular Biology.
[192] Tavares. The effects of meloxicam, indomethacin or NS‐398 on eicosanoid synthesis by fresh human gastric mucosa , 2000, Alimentary pharmacology & therapeutics.
[193] Megumi Baba,et al. Orthotopic implantation of a colon cancer xenograft induces high expression of cyclooxygenase-2. , 2003, Cancer letters.
[194] Soo Young Lee,et al. Molecular ordering of ROS production, mitochondrial changes, and caspase activation during sodium salicylate-induced apoptosis. , 2003, Free radical biology & medicine.
[195] W C Willett,et al. Aspirin and the risk of colorectal cancer in women. , 1995, The New England journal of medicine.
[196] K. Sugihara,et al. JTE‐522, a selective COX‐2 inhibitor, interferes with the growth of lung metastases from colorectal cancer in rats due to inhibition of neovascularization: A vascular cast model study , 2004, International journal of cancer.
[197] A. Ljubimov,et al. P450 in the angiogenesis affair: the unusual suspect. , 2005, The American journal of pathology.
[198] A. Plückthun,et al. Rate-determining step in phospholipase A2 mechanism. 18O isotope exchange determined by 13C NMR. , 1986, The Journal of biological chemistry.
[199] Rajnish A. Gupta,et al. 15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells. , 2001, Cancer research.
[200] Oliver Werz,et al. Therapeutic options for 5-lipoxygenase inhibitors. , 2006, Pharmacology & therapeutics.
[201] M. Kondo,et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. , 1995, Cancer research.
[202] C. Funk,et al. Prostaglandins and leukotrienes: advances in eicosanoid biology. , 2001, Science.
[203] S. Solomon,et al. Celecoxib for the prevention of sporadic colorectal adenomas. , 2006, The New England journal of medicine.
[204] Andreas Hoeft,et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. , 2005, The New England journal of medicine.
[205] K. Matsuo,et al. Breast cancer risk and erythrocyte compositions of n‐3 highly unsaturated fatty acids in Japanese , 2007, International journal of cancer.
[206] J. Mulshine,et al. Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors. , 1999, Cancer research.
[207] R. Copeland,et al. Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[208] Y. Denkins,et al. Role of omega-3 polyunsaturated fatty acids on cyclooxygenase-2 metabolism in brain-metastatic melanoma. , 2005, Journal of lipid research.
[209] Magnus Ingelman-Sundberg,et al. Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. , 2004, The American journal of clinical nutrition.
[210] P. Duke,et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. , 2003, The Journal of thoracic and cardiovascular surgery.
[211] V. Strand,et al. Effects of the Cyclooxygenase-2 Specific Inhibitor Valdecoxib Versus Nonsteroidal Antiinflammatory Agents and Placebo on Cardiovascular Thrombotic Events in Patients with Arthritis , 2004, American journal of therapeutics.
[212] T. Adrian,et al. Leukotriene B4 receptor antagonist LY293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[213] Ding Ma,et al. Cytochrome p450 epoxygenase promotes human cancer metastasis. , 2007, Cancer research.
[214] J. Chow,et al. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2 , 1996, Nature Structural Biology.
[215] C. Bombardier,et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison , 2006, The Lancet.
[216] E. Jacobs,et al. VEGF-induced relaxation of pulmonary arteries is mediated by endothelial cytochrome P-450 hydroxylase. , 2006, American journal of physiology. Lung cellular and molecular physiology.
[217] G. Cabral. Lipids as bioeffectors in the immune system. , 2005, Life sciences.